Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension-Reference-Cited by-全球学者库

Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension

Published:2016 Issue:6 Volume:80 Page:1478-1483
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Tahara Nobuhiro¹,Dobashi Hiroaki²,Fukuda Keiichi³,Funauchi Masanori⁴,Hatano Masaru⁵,Ikeda Satoshi⁶,Joho Shuji⁷,Kihara Yasuki⁸,Kimura Takeshi⁹,Kondo Takahisa¹⁰,Matsushita Masakazu¹¹,Minamino Tohru¹²,Nakanishi Norifumi¹³,Ozaki Yukio¹⁴,Saji Tsutomu¹⁵,Sakai Satoshi¹⁶,Tanabe Nobuhiro¹⁷,Watanabe Hiroshi¹⁸,Yamada Hidehiro¹⁹,Yoshioka Koichiro²⁰,Sasayama Shigetake²¹

Affiliation:

1. Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine

2. Department of Internal Medicine, Division of Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University

3. Department of Cardiology, Keio University School of Medicine

4. Department of Hematology and Rheumatology, Kindai University Faculty of Medicine

5. Department of Cardiovascular Medicine, The Uiversity of Tokyo Hospital

6. Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences

7. Second department of internal medicine, Toyama University Hospital

8. Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences

9. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University

10. Department of Advanced Medicine in Cardiopulmonary Disease, Nagoya University Graduate School of Medicine

11. Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine

12. Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences

13. Endowed Department of Pulmonary Hypertension and Pulmonary Vascular Medicine, National Cerebral and Cardiovascular Center Research Institute

14. Department of Cardiology, Fujita Health University Hospital

15. Department of Pediatrics, Toho University Omori Medical Center

16. Cardiovascular Division, Department of Clinical Medicine, Faculty of Medicine, University of Tsukuba

17. Department of Respirology and Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University

18. Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine

19. Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine

20. Department of Cardiovascular Medicine, Tokai University School of Medicine

21. Uji Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/80/6/80_CJ-15-1305/_pdf

Reference28 articles.

1. 1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.

2. 2. Nergui S, Fukumoto Y, Do.e Z, Nakajima S, Shimizu T, Ikeda S, et al. Role of endothelial nitric oxide synthase and collagen metabolism in right ventricular remodeling due to pulmonary hypertension. Circ J 2014; 78: 1465–1674.

3. 3. Dai Z, Sugimura K, Fukumoto Y, Tatebe S, Miura Y, Nochioka K, et al. Visualization of complete regression of pulmonary arterial remodeling on optical coherence tomography in a patient with pulmonary arterial hypertension. Circ J 2014; 78: 2771–2773.

4. 4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 35: 1425–1436.

5. 5. Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 2012; 55: 7849–7861.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis;The Clinical Respiratory Journal;2023-07-10

2. Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study;ERJ Open Research;2021-07

3. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues – a single‐centre experience;Pulmonary Circulation;2021-01

4. Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan;Kardiologiia;2020-06-19

5. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients;Current Medical Research and Opinion;2020-05-12